We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

PDGFR

PDGFR inhibitors block the platelet-derived growth factor receptors α and β (PDGFRα, PDGFRβ) of mesenchymal cells. Dimeric platelet-derived growth factor (PDGF) ligands bind the receptors, which then dimerize and autophosphorylate on tyrosine residues. PDGF signaling stimulates the growth and migration of fibroblasts, smooth muscle cells and pericytes, and it supports blood vessel maturation. Imatinib belongs to the 2-phenylaminopyrimidine class, first reported in 1995 as selective inhibitors of PDGF receptor signaling. Imatinib also inhibits the Abelson tyrosine kinase (Abl) and the stem cell factor receptor c-Kit. Sunitinib malate, axitinib and nintedanib act on PDGFR as part of broader profiles that include vascular endothelial growth factor receptors (VEGFRs). Compounds that act mainly on VEGFRs are listed in the sibling category VEGFR.

1 Item

  • SU 4313
    Cat. No.
    A22672
    CAS No.
    186611-55-2

    SU 4313

    SU-4313 is a small-molecule modulator of protein tyrosine kinases (PTKs). It inhibits multiple receptor tyrosine kinases with reported IC₅₀ values of 14.5 μM (PDGFR), 18.8 μM (FLK-1/VEGFR2), 11 μM (EGFR), 16.9 μM (HER2 kinase), and 8.0 μM (IGF-1R). Through its multi-kinase inhibitory profile, SU-4313 modulates tyrosine kinase–mediated signal transduction pathways involved in the regulation of cell proliferation and growth. It is therefore commonly used as a research tool for investigating aberrant receptor tyrosine kinase signaling and proliferation-associated pathways.  

    In stock View Details
    1 mg
    $30.00
    2 mg
    $45.00
    All 8 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...